AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee
On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.
Stocktwits·2d ago
More News
Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates
The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.
Stocktwits·9d ago
BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025
The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.
Stocktwits·13d ago
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.
Stocktwits·14d ago
JHG Stock Rockets 15% Pre-Market After Receiving A Non-Binding Proposal For $46 Per Share
Trian Fund Management said it beneficially owns 20.4% of the outstanding ordinary shares of Janus Henderson.
Stocktwits·17d ago
Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices
Stocktwits·17d ago
Albemarle To Sell Majority Stake In Ketjen’s Refining Catalyst Business To KPS Capital Partners
The company said that Albemarle and KPS, through affiliates, will own about 49% and 51% of Ketjen at close, respectively.
Stocktwits·17d ago
UnitedHealth’s Optum CFO Reportedly Exits In Less Than Six Months Into The Role
Stocktwits·20d ago
Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler
Stocktwits·22d ago
Hillenbrand To Go Private In Nearly $4B Deal With Affiliate Of Lone Star Funds
The company will be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price on August 12.
